BIOMAT Database Logo BIOMAT Database Logo

A prospective study of the clarithromycin-digoxin interaction in elderly patients. 2002

P Zapater, and S Reus, and A Tello, and D Torrús, and M Pérez-Mateo, and J F Horga
Department of Clinical Pharmacology, University General Hospital of Alicante, Maestro Alonso 109, 03010 Alicante, Spain. zapater_ped@gva.es

The study was a prospective observational trial carried out to assess the clarithromycin-digoxin interaction in elderly patients chronically taking digoxin. Digoxin concentrations were determined before and after concomitant treatment with clarithromycin. A Bayesian approach was used to calculate digoxin pharmacokinetics. In the seven patients who were studied there was a significant increase in digoxin concentration after 4-7 days of clarithromycin treatment; digoxin clearance and elimination rate constant were 56-60% lower and elimination half-life was 82% longer. The pharmacokinetic clarithromycin-digoxin interaction in the elderly may be much more frequent than has been assumed up to now.

UI MeSH Term Description Entries
D008297 Male Males
D010361 Patients Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures. Clients,Client,Patient
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

P Zapater, and S Reus, and A Tello, and D Torrús, and M Pérez-Mateo, and J F Horga
Comment: clarithromycin-digoxin interaction.
December 1999, The Annals of pharmacotherapy,
P Zapater, and S Reus, and A Tello, and D Torrús, and M Pérez-Mateo, and J F Horga
[Clarithromycin-digoxin: an unrecognized interaction in some patients].
April 1997, Presse medicale (Paris, France : 1983),
P Zapater, and S Reus, and A Tello, and D Torrús, and M Pérez-Mateo, and J F Horga
Clarithromycin-associated digoxin toxicity in the elderly.
January 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
P Zapater, and S Reus, and A Tello, and D Torrús, and M Pérez-Mateo, and J F Horga
Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin.
January 1999, The Annals of pharmacotherapy,
P Zapater, and S Reus, and A Tello, and D Torrús, and M Pérez-Mateo, and J F Horga
Risk of digoxin intoxication caused by clarithromycin-digoxin interactions in heart failure patients: a population-based study.
December 2009, European journal of clinical pharmacology,
P Zapater, and S Reus, and A Tello, and D Torrús, and M Pérez-Mateo, and J F Horga
Interaction between midazolam and clarithromycin in the elderly.
January 2008, British journal of clinical pharmacology,
P Zapater, and S Reus, and A Tello, and D Torrús, and M Pérez-Mateo, and J F Horga
Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction.
July 2003, British journal of clinical pharmacology,
P Zapater, and S Reus, and A Tello, and D Torrús, and M Pérez-Mateo, and J F Horga
[Digoxin in elderly patients].
December 1986, Nederlands tijdschrift voor geneeskunde,
P Zapater, and S Reus, and A Tello, and D Torrús, and M Pérez-Mateo, and J F Horga
Clarithromycin and digoxin toxicity.
April 1998, Annals of internal medicine,
P Zapater, and S Reus, and A Tello, and D Torrús, and M Pérez-Mateo, and J F Horga
Clarithromycin-induced digoxin intoxication.
September 1997, The Annals of pharmacotherapy,
Copied contents to your clipboard!